ALLO
Price
$2.17
Change
-$0.09 (-3.98%)
Updated
Feb 21 closing price
Capitalization
454.99M
4 days until earnings call
EDIT
Price
$1.92
Change
-$0.14 (-6.80%)
Updated
Feb 21 closing price
Capitalization
158.49M
4 days until earnings call
Ad is loading...

ALLO vs EDIT

Header iconALLO vs EDIT Comparison
Open Charts ALLO vs EDITBanner chart's image
Allogene Therapeutics
Price$2.17
Change-$0.09 (-3.98%)
Volume$4.88M
Capitalization454.99M
Editas Medicine
Price$1.92
Change-$0.14 (-6.80%)
Volume$9.47M
Capitalization158.49M
ALLO vs EDIT Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. EDIT commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and EDIT is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ALLO: $2.84 vs. EDIT: $1.74)
Brand notoriety: ALLO and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 1385% vs. EDIT: 363%
Market capitalization -- ALLO: $454.99M vs. EDIT: $158.49M
ALLO [@Biotechnology] is valued at $454.99M. EDIT’s [@Biotechnology] market capitalization is $158.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than EDIT.

Price Growth

ALLO (@Biotechnology) experienced а +102.86% price change this week, while EDIT (@Biotechnology) price change was +47.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

ALLO is expected to report earnings on Apr 30, 2025.

EDIT is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($455M) has a higher market cap than EDIT($158M). EDIT YTD gains are higher at: 37.008 vs. ALLO (33.333). EDIT has higher annual earnings (EBITDA): -222.63M vs. ALLO (-256.67M). ALLO has more cash in the bank: 292M vs. EDIT (265M). EDIT has less debt than ALLO: EDIT (38.5M) vs ALLO (85.1M). EDIT has higher revenues than ALLO: EDIT (61.8M) vs ALLO (43K).
ALLOEDITALLO / EDIT
Capitalization455M158M288%
EBITDA-256.67M-222.63M115%
Gain YTD33.33337.00890%
P/E RatioN/AN/A-
Revenue43K61.8M0%
Total Cash292M265M110%
Total Debt85.1M38.5M221%
FUNDAMENTALS RATINGS
ALLO vs EDIT: Fundamental Ratings
ALLO
EDIT
OUTLOOK RATING
1..100
8826
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3862
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (18) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that EDIT’s stock grew significantly faster than ALLO’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that EDIT’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (98). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

ALLO's Price Growth Rating (38) in the Biotechnology industry is in the same range as EDIT (62). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

ALLO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOEDIT
RSI
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
85%
Momentum
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
77%
MACD
ODDS (%)
Bullish Trend 5 days ago
80%
N/A
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 5 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 5 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
85%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
89%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+39.22%
FATE - ALLO
59%
Loosely correlated
+7.75%
NTLA - ALLO
58%
Loosely correlated
+7.76%
CRSP - ALLO
57%
Loosely correlated
+5.03%
EDIT - ALLO
56%
Loosely correlated
+26.09%
PRME - ALLO
53%
Loosely correlated
+5.28%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+26.09%
NTLA - EDIT
61%
Loosely correlated
+7.76%
CRSP - EDIT
60%
Loosely correlated
+5.03%
BEAM - EDIT
53%
Loosely correlated
+3.36%
PRME - EDIT
52%
Loosely correlated
+5.28%
ALLO - EDIT
50%
Loosely correlated
+39.22%
More